Wild oat is the most economically detrimental weed species in the Canadian Prairies and effective herbicidal control options are limited due to widespread resistance to ACCase inhibitors, ALS inhibitors, and lipid biosynthesis inhibitors; therefore, evaluation of new herbicidal modes of action such as pyroxasulfone and sulfentrazone for control is critical. Two wild oat populations (HR08-210 and HR11-151) were first subjected to a discriminating dose screen to characterize resistance to ACCase and ALS inhibiting herbicides in comparison with a susceptible population (S1988). Dose-response experiments with triallate, pyroxasulfone, and sulfentrazone were then conducted to evaluate potential cross-resistance. Screening indicated both herbicide-resistant (HR) populations were resistant to ACCase- and ALS inhibiting herbicides, most likely due to enhanced metabolism and an ACCase mutation. HR08-210 and HR11-151 were resistant to triallate (resistance ratios of 2.53 and 3.39, respectively), but cross-resistance to pyroxasulfone (2.78) and sulfentrazone (2.0) was only observed in HR11-151. Results indicate previously selected resistance to ACCase and ALS inhibitors (enhanced metabolism and ACCase mutation) or triallate (enhanced endogenous gibberellins) could limit the utility of new herbicide modes of action for control of wild oat.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.